SETD2 and neoplasm: Furthermore, an experimental study in renal cell carcinoma found that SETD2 acts as a transcription factor regulating E3 ubiquitin ligase FBW7 target gene expression, causing altered PD-L1 expression levels and promoting CD4+ and CD8+ T cell infiltration and enhancing the anti-tumor effects of PD-1 antibodies (48).